期刊文献+

来氟米特治疗慢性进展性IgA肾病的疗效观察 被引量:11

下载PDF
导出
摘要 目的比较来氟米特与环磷酰胺治疗慢性进展性IgA肾病的临床疗效、不良反应及复发率。方法收集2005年4月至2008年5月本院肾内科符合条件的60例IgA肾病患者,30例治疗组接受来氟米特联合激素治疗,30例对照组接受激素联合环磷酰胺治疗,观察治疗前和治疗后2、4、8、12、16、20、24周的相关临床指标变化,并进行评价。结果两组疗效相同,但来氟米特治疗组不良反应明显低于环磷酰胺对照组。结论来氟米特联合激素方案可以作为治疗慢性进展性IgA肾病的选择之一,且安全、有效。
机构地区 丽水市人民医院
出处 《浙江实用医学》 2009年第2期107-108,110,共3页 Zhejiang Practical Medicine
  • 相关文献

参考文献11

  • 1Donadio J V, Grande J P. IgA nephropathy. N Engl J Med, 2002, 347:738
  • 2Dillon J J.Treating IgA nephropathy. J Am Soc Nephrol, 2001,12: 846
  • 3聂莉芳,于大君,余仁欢,孙建实,方敬爱,何立群,张胜容,王暴魁.IgA肾病综合临床疗效评价标准研究[J].中国中西医结合肾病杂志,2003,4(11):671-672. 被引量:27
  • 4Floege J. Evidenced baced recommendations for immtmo supperession in IgA nephropathy: handle with caution. Nephrol Dia Transplant. 2003.18:241
  • 5Bllardie F W, Roberts I S. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol. 2002,13:142
  • 6Urushibara M,TakayanagiH,koga T, et al. The antirhenatic atic drug leflunom ide inhibits osteoclastogenesis byinterfering with receptor activator of NF - kappa B ligand - stin u hriflated induction of nuclear factor of activated T cells el. Arthritis Rheum,2004, (3)794
  • 7Miceli - Richard C, Dougados M, Leflunom ide for the treament of rheumatoid arthritis. Expert Opin Phamacother 2003,4 (6) :987
  • 8Dimitrova P, Skapenko A, Schleyerbach R, et al. Immunomodulatory functions of leflunom ide inhibition of T helper TH 1 cell activation and promotion of TH 2 differentiation. Arthritis Rheum,2001,44(9)216
  • 9Hansen K E, Cush J, Singhal A, et al The safety and efficacy of leflunom ide in combination with inflixinab in rhoamatoid arthritis. Arthritis Rheum,2004,51 (22):228
  • 10余荣杰,吴雄飞,赵洪雯,方路.来氟米特治疗难治性肾病综合征27例报道[J].重庆医学,2003,32(6):694-695. 被引量:34

二级参考文献14

  • 1王海燕 郑法雷 等.原发性肾小球疾病分型与治疗及诊断标准专题座谈会纪要[J].中华内科杂志,1993,2:131-134.
  • 2Williams JW, Mira1 D, Chong A, et al. Experienees with leflunomide in solid organ transplantation[J]. Transplantation,2002,15(73) :358.
  • 3Choi MJ, Eustsce JA, Gimenez LF, et al. Myeophenolate mofetil treatment for primary glomerular diseases[J].Kidney Int,2002 ,61:1098.
  • 4Pascual J, Orte J, Marcen R, et al. Use of leflunomide in human renal transplantation [J]. Transplantation, 2001,72:1709.
  • 5Thomson AW, Starzl TE. New immunosuppressive drugs: mechanistic insights and potential therapeutic advances[J]. Immunol Rev, 1993,136 : 71.
  • 6Schena FP. Primary glomerulonephritides with nephrotic syndrome. Limitations of therapy in adult patients[J]. J Nephrol,1999 ,12(Suppl 2) :S125.
  • 7Amitabyh P. Leflunomide: a review of its use in active rheumatoid arhtritis. Drugs, 1999, 58 (6): 1137-1164
  • 8Xiulong X, James W, Williams, et al. Inhibition of protein tyrosine phosphlorylationin T cell by novel immunosuppressive agent,leflunomide. Biol Chem, 1995, 270 (21): 12398 -12403
  • 9Thoenes G. Leflunomide inhibits experimental autoimmune tubulinterstital nephritis in rats. INT J Immunopharmac, 1998, 11(2): 921 -929
  • 10Remer CF, Weisman MH, Wallace DJ. Benefits of leflunomide in systemic lupus erythematosus. Lupus, 2001, 10 (7): 480 -483

共引文献87

同被引文献142

引证文献11

二级引证文献74

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部